Equity Overview
Price & Market Data
Price: $5.12
Daily Change: $0.00 / 0.00%
Daily Range: $4.29 - $5.26
Market Cap: $255,457,952
Daily Volume: 895,334
Performance Metrics
1 Week: 10.11%
1 Month: -39.98%
3 Months: -37.41%
6 Months: -14.38%
1 Year: -18.21%
YTD: -37.41%
Company Details
Employees: 50
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.